Nusinersen, an antisense oligonucleotide drug for spinal muscular atrophy

被引：0
|
作者：
David R Corey
机构：
[1] UT Southwestern,David R. Corey is in the Departments of Pharmacology and Biochemistry
[2] Dallas,undefined
[3] Texas,undefined
[4] USA.,undefined
来源：
Nature Neuroscience | 2017年 / 20卷
关键词：
D O I：
暂无
中图分类号：
学科分类号：
摘要：
Nusinersen (Spinraza) is a recently approved drug for treating spinal muscular atrophy. Approval of nusinersen may signal new opportunities for using antisense oligonucleotides as treatments for devastating neurological diseases.
引用
收藏
页码：497 / 499
页数：2
相关论文
共 50 条
  • [1] Nusinersen, an antisense oligonucleotide drug for spinal muscular atrophy
    Corey, David R.
    [J]. NATURE NEUROSCIENCE, 2017, 20 (04) : 497 - 499
  • [2] The Antisense Oligonucleotide Nusinersen for Treatment of Spinal Muscular Atrophy
    Edinoff, Amber N.
    Nguyen, Long H.
    Odisho, Amira S.
    Maxey, Benjamin S.
    Pruitt, John W.
    Girma, Brook
    Cornett, Elyse M.
    Kaye, Adam M.
    Kaye, Alan D.
    [J]. ORTHOPEDIC REVIEWS, 2021, 13 (02)
  • [3] Nusinersen: antisense oligonucleotide to increase SMN protein production in spinal muscular atrophy
    Paton, D. M.
    [J]. DRUGS OF TODAY, 2017, 53 (06) : 327 - 337
  • [4] Phase 2 study design of antisense oligonucleotide nusinersen in presymptomatic infants with spinal muscular atrophy
    Bertini, E.
    Hwu, P.
    Reyna, S.
    Farwell, W.
    De, D.
    [J]. NEUROMUSCULAR DISORDERS, 2016, 26 : S210 - S210
  • [5] NCALD Antisense Oligonucleotide Therapy in Addition to Nusinersen further Ameliorates Spinal Muscular Atrophy in Mice
    Torres-Benito, Laura
    Schneider, Svenja
    Rombo, Roman
    Ling, Karen K.
    Grysko, Vanessa
    Upadhyay, Aaradhita
    Kononenko, Natalia L.
    Rigo, Frank
    Bennett, C. Frank
    Wirth, Brunhilde
    [J]. AMERICAN JOURNAL OF HUMAN GENETICS, 2019, 105 (01) : 221 - 230
  • [6] A Semi-Mechanistic Population Pharmacokinetic Model of Nusinersen: An Antisense Oligonucleotide for the Treatment of Spinal Muscular Atrophy
    Biliouris, Konstantinos
    Gaitonde, Puneet
    Yin, Wei
    Norris, Daniel A.
    Wang, Yanfeng
    Henry, Scott
    Fey, Robert
    Nestorov, Ivan
    Schmidt, Stephan
    Rogge, Mark
    Lesko, Lawrence J.
    Trame, Mirjam N.
    [J]. CPT-PHARMACOMETRICS & SYSTEMS PHARMACOLOGY, 2018, 7 (09): : 581 - 592
  • [7] Antisense oligonucleotide mediated therapy of spinal muscular atrophy
    Sivanesan, Senthilkumar
    Howell, Matthew D.
    DiDonato, Christine J.
    Singh, Ravindra N.
    [J]. TRANSLATIONAL NEUROSCIENCE, 2013, 4 (01) : 1 - 7
  • [8] A pediatric quantitative systems pharmacology model of neurofilament trafficking in spinal muscular atrophy treated with the antisense oligonucleotide nusinersen
    Paris, Alessio
    Bora, Pranami
    Parolo, Silvia
    MacCannell, Drew
    Monine, Michael
    van der Munnik, Nick
    Tong, Xiao
    Eraly, Satish
    Berger, Zdenek
    Graham, Danielle
    Ferguson, Toby
    Domenici, Enrico
    Nestorov, Ivan
    Marchetti, Luca
    [J]. CPT-PHARMACOMETRICS & SYSTEMS PHARMACOLOGY, 2023, 12 (02): : 196 - 206
  • [9] Nusinersen for spinal muscular atrophy
    Wurster, Claudia D.
    Ludolph, Albert C.
    [J]. THERAPEUTIC ADVANCES IN NEUROLOGICAL DISORDERS, 2018, 11
  • [10] Nusinersen: A Treatment for Spinal Muscular Atrophy
    Claborn, Melanie K.
    Stevens, Debra L.
    Walker, Cheri K.
    Gildon, Brooke L.
    [J]. ANNALS OF PHARMACOTHERAPY, 2019, 53 (01) : 61 - 69
12345